Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabidiol (CBD) as an Adjunct to Treatment in Early Psychosis
NCT04411225Phase 3Recruiting
- Sponsor
- University of California, San Diego
- Start
- Jun 2022
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of cannabidiol in psychosis, sponsored by University of California, San Diego. Started Jun 2022; status: recruiting.
02
Drugs
cannabidiol
03
Conditions
psychosis
Beyond the preview
Go deeper on NCT04411225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04411225.